Do Female Age and Body Weight Modify the Effect of Individualized FSH Dosing in IVF/ICSI Treatment? A Secondary Analysis of the OPTIMIST Trial

The OPTIMIST trial revealed that for women starting in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment, no substantial differences exist in first cycle and cumulative live birth rates between an antral follicle count (AFC)‐based individualized follicle‐stimulating hormone (FSH) dose and a standard dose. Female age and body weight have been suggested to cause heterogeneity in the effect of FSH dose individualization. The objective of the current study is to evaluate whether these patient characteristics modify the effect of AFC‐based individualized FSH dosing in IVF/ICSI treatment.